TEJ-KOHLI-FOUNDATION
19.12.2019 14:11:12 CET | Business Wire | Press release
On the fourth anniversary of the Tej Kohli Cornea Institute in Hyderabad, the Tej Kohli Foundation has renewed its commitment of $14m of funding from 2020. During 2019 5,736 individuals were cured of blindness or severe visual impairment at The Tej Kohli Cornea Institute, which is a collaboration between the Tej Kohli Foundation in London, and the LV Prasad Eye Institute in Hyderabad, a World Health Organization Collaborating Centre.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191219005417/en/
The Tej Kohli Cornea Institute was inaugurated in December 2015 to tackle the problem of poverty blindness by providing free treatment to anyone who needs it. Since its inauguration the Cornea Institute has taken care of 223,404 outpatients, completed 43,255 surgical procedures, collected 38,225 donor corneas into its eye bank, utilized 22,176 donor corneas, trained 152 clinicians, published 202 papers and given 892 educational presentations.
Reaching people living with blindness and severe visual impairment in the hard-to-reach rural areas where 66% of Indians live is a particular challenge that the Tej Kohli Cornea Institute is uniquely solving. A unique presence of eye care centres in villages supplemented with a fully equipped mobile diagnostics van take eye care directly to hard-to-reach patients, with more than 100 corneal transplants completed so far in these rural areas.
Other 2019 operational highlights at the Tej Kohli Cornea Institute included:
- 280,000 individuals called the ‘Call Netra’ toll free eye care helpline.
- A special privilege ‘Keratoplasty card’ was issued to corneal transplant patients to ensure priority check-ups and access to care anytime and anywhere.
- An education app was launched to continually assess cornea doctors in their evaluations.
- The ECHO project linked expert specialist teams with clinicians in remote local communities.
According to the World Health Organisation, 90% of those affected by blindness and severe visual impairment live in the poorest countries in the world. 14m live in India, where between 6m and 7m people are currently waiting for a corneal transplant. At least 300,000 children in India have some form of severe visual impairment or blindness.
Whilst approximately 75% of corneal disease is curable, the costs of corneal transplantation surgery using donor cornea, and the many years of medicine needed to prevent rejection, makes treatment inaccessible to many. Born out of a partnership with the LV Prasad Eye Institute and the Tej Kohli Foundation, the Tej Kohli Cornea Institute is focussed on prevention, treatment and cure at no cost directly into these high-impact populations that are living needlessly with corneal blindness.
Dr Pravin K Vaddavalli, MD, Director of Tej Kohli Cornea Institute said:
“The last four years have been an opportunity to assess the magnitude of the problem of corneal blindness, create strategic partnerships to expand our reach and start to evolve ways and means to allow these patients to live longer, more productively and with dignity.”
Wendy Kohli, co-Founder of the Tej Kohli Foundation said:
“It’s an uncomfortable reality that millions of people worldwide are living with curable blindness that persists entirely because they cannot afford to access treatment. The impact of restoring a person’s vision on that person’s confidence, wellbeing and economic prospects is substantial. Through the Tej Kohli Cornea Institute we are able to make direct interventions into individual lives that help and transform entire families every single day.”
---
About The Tej Kohli Cornea Institute
The mission of the Tej Kohli Cornea Institute is to prevent, control and eliminate corneal blindness worldwide. The Institute is a global leader in research and development, preventative medicine, education and cornea transplants. The Institute enables access to affordable treatment through systemic long-term efforts to create widespread access to high-quality eye care facilities that are delivered by people with the resources, technical skills and compassion to handle diverse population segments.
http://www.tejkohlicorneainstitute.com
About LV Prasad Eye Institute
Established in 1987, the LV Prasad Eye Institute (LVPEI), a World Health Organization Collaborating Centre for Prevention of Blindness, is a comprehensive eye health facility. The Institute has ten active arms to its areas of operations: Clinical Services, Education, Research, Vision Rehabilitation, Rural and Community Eye Health, Eye Banking, Advocacy and Policy Planning, Capacity Building, Innovation and Product Development. LVPEI's mission is to provide equitable and quality eye care to all sections of society.
About the Tej Kohli Foundation
Founded in 2005, the Tej Kohli Foundation seeks to make interventions that transform individual lives. It is best known for its global mission to end corneal blindness worldwide. Since 2015 the Foundation has funded the provision of corneal transplants in underserved communities in India through the Tej Kohli Cornea Institute; and in 2019 the Foundation gifted $2m to Mass Eye and Ear in Boston, a teaching hospital of Harvard Medical School, to support the development of new technologies to cure blindness. In December 2019 the Foundation launched the ‘Future Bionics’ program to gift 3D printed bionic arms to children and young people who are living with limb difference in the United Kingdom.
http://www.tejkohlifoundation.com
END
View source version on businesswire.com: https://www.businesswire.com/news/home/20191219005417/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
